Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species

Trial Profile

Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Piperacillin/tazobactam (Primary) ; Meropenem
  • Indications Escherichia coli infections; Klebsiella infections
  • Focus Therapeutic Use
  • Acronyms MERINO
  • Most Recent Events

    • 11 Sep 2018 Primary endpoint (Mortality at 30 days) has not been met, according to the results published in the JAMA: the Journal of the American Medical Association
    • 11 Sep 2018 Results published in the JAMA: the Journal of the American Medical Association
    • 22 Nov 2017 Status changed from recruiting to discontinued, secondary to third interim analysis by the study DSMB
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top